FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807391987> ?p ?o ?g. }

• W2807391987 endingPage "1007" @default.
• W2807391987 startingPage "1007" @default.
• W2807391987 abstract "1007 Background: The PI3K/AKT signalling pathway is frequently activated in triple-negative breast cancer (TNBC). AZD5363 is a highly-selective, oral, small molecule AKT inhibitor. The PAKT trial investigated the addition of AZD5363 to paclitaxel as 1st-line therapy for TNBC. Methods: This investigator-led, double-blind, placebo-controlled, randomised phase II trial, recruited women with previously untreated, metastatic TNBC at 42 sites in 6 countries. Patients were randomly assigned (1:1) to paclitaxel 90mg/m2 (days 1, 8, & 15) with either AZD5363 (400mg BD) or placebo (days 2-5, 9-12, 16-19) every 28 days until disease progression or unacceptable toxicity. The primary endpoint was progression‐free survival (PFS). Secondary endpoints included overall survival (OS), PFS in the subgroup with PIK3CA/AKT1/PTEN-alterations, response, and safety. Results: Between 05/2014 and 06/2017, 140 patients were randomised to paclitaxel + AZD5363 (n = 70) or paclitaxel + placebo (n = 70). Median duration of follow-up was 18.2 months (95% CI, 13.6 to 24.0). In the ITT analysis, median PFS was 5.9 months (m) for AZD5363 compared to 4.2m for placebo (hazard ratio [HR], 0.75; 95% CI, 0.52 to 1.08; one-sided p = 0.06; two-sided p = 0.11 [predefined significance level of 0.10, one-sided]). Median OS was 19.1m for AZD5363 compared to 12.6m for placebo (HR, 0.64; 95% CI, 0.40 to 1.01; one-sided p = 0.02; two-sided p = 0.04). Results for the subgroup with PIK3CA/AKT1/PTEN-altered tumours will be presented. Most common grade 3 or worse adverse events were diarrhoea (12% [8/68] of AZD5363-treated patients vs 1% [1/70] of placebo-treated patients), infection (4% vs 1%), neutropenia (3% vs 3%), rash (4% vs 0) and fatigue (4% vs 0). Conclusions: The trial met its primary endpoint. Addition of AZD5363 to 1st-line paclitaxel therapy for TNBC resulted in significantly longer PFS and OS. AZD5363 warrants further investigation for the treatment of TNBC. Clinical trial information: NCT02423603." @default.
• W2807391987 created "2018-06-13" @default.
• W2807391987 creator A5007089296 @default.
• W2807391987 creator A5008920583 @default.
• W2807391987 creator A5014159829 @default.
• W2807391987 creator A5014243045 @default.
• W2807391987 creator A5014544240 @default.
• W2807391987 creator A5015824949 @default.
• W2807391987 creator A5019696786 @default.
• W2807391987 creator A5031415556 @default.
• W2807391987 creator A5032686530 @default.
• W2807391987 creator A5038092151 @default.
• W2807391987 creator A5056505692 @default.
• W2807391987 creator A5058756575 @default.
• W2807391987 creator A5060044961 @default.
• W2807391987 creator A5065435228 @default.
• W2807391987 creator A5069401956 @default.
• W2807391987 creator A5075498749 @default.
• W2807391987 creator A5080215197 @default.
• W2807391987 creator A5089578927 @default.
• W2807391987 creator A5089861374 @default.
• W2807391987 creator A5090257791 @default.
• W2807391987 date "2018-05-20" @default.
• W2807391987 modified "2023-10-16" @default.
• W2807391987 title "AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial." @default.
• W2807391987 doi "https://doi.org/10.1200/jco.2018.36.15_suppl.1007" @default.
• W2807391987 hasPublicationYear "2018" @default.
• W2807391987 type Work @default.
• W2807391987 sameAs 2807391987 @default.
• W2807391987 citedByCount "48" @default.
• W2807391987 countsByYear W28073919872018 @default.
• W2807391987 countsByYear W28073919872019 @default.
• W2807391987 countsByYear W28073919872020 @default.
• W2807391987 countsByYear W28073919872021 @default.
• W2807391987 countsByYear W28073919872022 @default.
• W2807391987 countsByYear W28073919872023 @default.
• W2807391987 crossrefType "journal-article" @default.
• W2807391987 hasAuthorship W2807391987A5007089296 @default.
• W2807391987 hasAuthorship W2807391987A5008920583 @default.
• W2807391987 hasAuthorship W2807391987A5014159829 @default.
• W2807391987 hasAuthorship W2807391987A5014243045 @default.
• W2807391987 hasAuthorship W2807391987A5014544240 @default.
• W2807391987 hasAuthorship W2807391987A5015824949 @default.
• W2807391987 hasAuthorship W2807391987A5019696786 @default.
• W2807391987 hasAuthorship W2807391987A5031415556 @default.
• W2807391987 hasAuthorship W2807391987A5032686530 @default.
• W2807391987 hasAuthorship W2807391987A5038092151 @default.
• W2807391987 hasAuthorship W2807391987A5056505692 @default.
• W2807391987 hasAuthorship W2807391987A5058756575 @default.
• W2807391987 hasAuthorship W2807391987A5060044961 @default.
• W2807391987 hasAuthorship W2807391987A5065435228 @default.
• W2807391987 hasAuthorship W2807391987A5069401956 @default.
• W2807391987 hasAuthorship W2807391987A5075498749 @default.
• W2807391987 hasAuthorship W2807391987A5080215197 @default.
• W2807391987 hasAuthorship W2807391987A5089578927 @default.
• W2807391987 hasAuthorship W2807391987A5089861374 @default.
• W2807391987 hasAuthorship W2807391987A5090257791 @default.
• W2807391987 hasConcept C121608353 @default.
• W2807391987 hasConcept C126322002 @default.
• W2807391987 hasConcept C142724271 @default.
• W2807391987 hasConcept C143998085 @default.
• W2807391987 hasConcept C168563851 @default.
• W2807391987 hasConcept C203092338 @default.
• W2807391987 hasConcept C204787440 @default.
• W2807391987 hasConcept C207103383 @default.
• W2807391987 hasConcept C27081682 @default.
• W2807391987 hasConcept C2775930923 @default.
• W2807391987 hasConcept C2776694085 @default.
• W2807391987 hasConcept C2777292972 @default.
• W2807391987 hasConcept C2780110267 @default.
• W2807391987 hasConcept C2780739268 @default.
• W2807391987 hasConcept C44249647 @default.
• W2807391987 hasConcept C530470458 @default.
• W2807391987 hasConcept C71924100 @default.
• W2807391987 hasConcept C90924648 @default.
• W2807391987 hasConceptScore W2807391987C121608353 @default.
• W2807391987 hasConceptScore W2807391987C126322002 @default.
• W2807391987 hasConceptScore W2807391987C142724271 @default.
• W2807391987 hasConceptScore W2807391987C143998085 @default.
• W2807391987 hasConceptScore W2807391987C168563851 @default.
• W2807391987 hasConceptScore W2807391987C203092338 @default.
• W2807391987 hasConceptScore W2807391987C204787440 @default.
• W2807391987 hasConceptScore W2807391987C207103383 @default.
• W2807391987 hasConceptScore W2807391987C27081682 @default.
• W2807391987 hasConceptScore W2807391987C2775930923 @default.
• W2807391987 hasConceptScore W2807391987C2776694085 @default.
• W2807391987 hasConceptScore W2807391987C2777292972 @default.
• W2807391987 hasConceptScore W2807391987C2780110267 @default.
• W2807391987 hasConceptScore W2807391987C2780739268 @default.
• W2807391987 hasConceptScore W2807391987C44249647 @default.
• W2807391987 hasConceptScore W2807391987C530470458 @default.
• W2807391987 hasConceptScore W2807391987C71924100 @default.
• W2807391987 hasConceptScore W2807391987C90924648 @default.
• W2807391987 hasIssue "15_suppl" @default.
• W2807391987 hasLocation W28073919871 @default.
• W2807391987 hasOpenAccess W2807391987 @default.
• W2807391987 hasPrimaryLocation W28073919871 @default.
• W2807391987 hasRelatedWork W2029752720 @default.

• next